Beyond Mounjaro: The Next Generation of Weight Loss Medications

​

Introduction

​

Last Tuesday, a patient who's been doing remarkably well on Mounjaro for eight months came to her review appointment with her phone already open to a health news website. "I keep seeing these articles about Retatrutide and something called CagriSema," she said. "Are these just different brand names for the same thing? Should I be thinking about switching? Am I missing out on something better?"

It's a question I'm hearing weekly now, and it reflects both the excitement and confusion surrounding what's genuinely a remarkable moment in obesity medicine. We're not just seeing incremental improvements to existing treatments—we're witnessing fundamentally different approaches that may reshape how we think about pharmacological weight management.

Let me walk you through what's actually happening in the development pipeline, what these new medications are, how they differ from current options, and perhaps most importantly, what this means for patients navigating weight loss treatment today.

​

The Landscape We're Operating In

​

To understand where we're heading, it helps to appreciate where we currently stand. Mounjaro and Wegovy have genuinely transformed obesity treatment over the past few years. When I started prescribing weight loss medications twenty years ago, our options produced modest results—perhaps 5-7% body weight loss if we were lucky, often with problematic side effects that limited long-term use.

Today, with tirzepatide and semaglutide, we're routinely seeing 15-20% weight loss sustained over twelve to eighteen months. These aren't marginal improvements; they're outcomes that approach what we historically only achieved through bariatric surgery. Patients who've struggled with obesity for decades are finally experiencing meaningful, sustained weight reduction that transforms their metabolic health.

But the pharmaceutical industry hasn't stopped innovating. Multiple companies are developing next-generation treatments that either build upon GLP-1 mechanisms or explore entirely different pathways. Three agents in particular—retatrutide, CagriSema, and orforglipron—represent distinct approaches that may offer advantages over current options.

​

Retatrutide: The Triple Threat

​

If Mounjaro represented a breakthrough by targeting two hormonal pathways instead of one, retatrutide takes this approach further by activating three distinct receptors simultaneously. Developed by Eli Lilly, it's what we call a triple agonist, affecting GIP, GLP-1, and glucagon receptors.

The glucagon component represents the key innovation here. While GIP and GLP-1 primarily work by suppressing appetite and regulating blood glucose, glucagon activation does something different—it increases energy expenditure and promotes the breakdown of stored fat. In theory, this creates a dual effect: you're eating less because of appetite suppression while simultaneously burning more calories through increased metabolic rate.

The Phase 2 trial data, published in the New England Journal of Medicine in mid-2023, showed average weight loss of 24.2% at the highest dose over 48 weeks. Let me put that in perspective—for someone weighing 110kg, that's roughly 26-27kg lost in less than a year. Those are remarkable numbers, genuinely approaching the upper end of what we see with sleeve gastrectomy.

But here's where my clinical experience makes me cautiously optimistic rather than unreservedly enthusiastic. Phase 2 trials involve carefully selected participants, intensive support systems, and close monitoring that doesn't reflect typical clinical practice. Real-world effectiveness typically runs about 70-80% of trial results. Additionally, these were relatively short-term studies—we have limited data on what happens at two, three, or five years.

The glucagon component also raises questions we can't yet fully answer. Glucagon activation can affect blood sugar regulation in complex ways, potentially causing issues in certain patients. How does long-term glucagon stimulation affect liver function, given the liver's central role in glucagon's metabolic effects? Will the increased energy expenditure lead to greater lean muscle loss during rapid weight reduction? These aren't reasons to dismiss retatrutide—they're simply unknowns that require thorough investigation.

From a practical standpoint, retatrutide remains in Phase 3 clinical trials. Even with successful completion, regulatory approval by the MHRA typically takes 12-18 months, followed by NICE technology appraisal for NHS commissioning decisions. Realistic UK availability, if everything proceeds smoothly, likely sits somewhere in 2026-2027. Private prescription might come sooner, but expect premium pricing—probably £300-400 monthly initially, given development costs and the improved efficacy profile.

​

CagriSema: The Combination Approach

​

Novo Nordisk has taken a philosophically different route with CagriSema. Rather than engineering a single molecule that hits multiple targets, they've combined two distinct medications in a fixed-dose formulation: semaglutide (the active ingredient in Wegovy) and cagrilintide, a long-acting amylin analogue.

Amylin might not be familiar to many patients, but it's a hormone naturally produced by the pancreas alongside insulin. It complements GLP-1 activity through different mechanisms—it slows gastric emptying (which prolongs feelings of fullness), suppresses glucagon secretion when it's inappropriately elevated, and acts on brain centres that regulate appetite. The idea behind combining it with semaglutide is that hitting appetite regulation through two complementary pathways might produce greater effects than either alone.

The REDEFINE-1 trial showed approximately 15.6% weight loss over 32 weeks with the combination compared to about 9.8% with semaglutide alone—a meaningful improvement. However, the trial duration was relatively short, making direct comparisons with longer Mounjaro or Wegovy studies difficult. What particularly interests me clinically is whether the combination might offer better tolerability than pushing semaglutide to maximum doses. Some patients struggle with the gastrointestinal side effects of high-dose GLP-1 agonists; perhaps achieving similar efficacy through dual mechanisms at moderate doses of each might ease this burden.

One patient I'm thinking of, David, lost 18kg on Wegovy but could never tolerate the step-up to 2.4mg weekly due to persistent nausea. He's maintained his weight loss at 1.7mg, which is excellent, but he'd hoped to lose another 8-10kg. CagriSema, when available, might offer him that option—greater efficacy without requiring maximal GLP-1 receptor activation.

Like retatrutide, CagriSema remains in clinical development with similar timeframes for potential UK availability. The combination approach might actually face additional regulatory scrutiny, as authorities typically want to see that combination therapy offers advantages over simply optimizing doses of individual components. That said, Novo Nordisk is a sophisticated company with extensive regulatory experience; they wouldn't be pursuing Phase 3 trials without confidence in the approval pathway.

​

Orforglipron: The Oral Alternative

​

There's a third development worth mentioning, though it's slightly behind the others in development: orforglipron, an oral GLP-1 receptor agonist from Eli Lilly. This might not sound revolutionary—after all, we already have oral semaglutide (Rybelsus) for diabetes—but orforglipron represents a different molecular structure designed specifically for once-daily oral dosing with reliable absorption.

Why does this matter? Because while once-weekly injections are convenient for many patients, some people genuinely struggle with self-injection. It's not about pain—these are tiny needles that most people barely feel. It's psychological. I've had patients who desperately wanted GLP-1 treatment but couldn't overcome their needle phobia, even with considerable support and gradual exposure attempts.

Phase 2 data showed orforglipron produced about 14.7% weight loss at the highest dose over 36 weeks, which is respectable though somewhat below injectable options. The question is whether slightly lower efficacy is an acceptable trade-off for oral administration. For needle-phobic patients, absolutely. For others, it depends on individual preferences and how the pricing structures develop.

​

The Superiority Question

​

Patients often want to know: which medication is best? It's a reasonable question without a straightforward answer, at least not yet. The simple truth is we lack head-to-head comparison trials. Retatrutide showed 24.2% weight loss over 48 weeks; Mounjaro showed 20.9% over 72 weeks; CagriSema showed 15.6% over 32 weeks. These numbers come from different trials with different patient populations, different support structures, and different durations. Direct comparison is problematic at best, misleading at worst.

What I can tell you is that even modest percentage differences translate meaningfully at the individual patient level. The difference between 16% and 21% weight loss for someone weighing 120kg is about 6kg—significant both clinically and personally. But efficacy is only one factor in treatment selection. Side effect profiles matter enormously. A medication producing 25% weight loss is useless if you can't tolerate it well enough to persist with treatment.

Cost will be a major consideration. Current GLP-1 medications cost £200-250 monthly for private patients. Newer agents will likely command premium pricing initially, potentially £300-400 monthly. That's a substantial financial commitment, and the incremental benefit of slightly higher efficacy may not justify the additional cost for everyone.

Availability is perhaps the most important practical factor. Medications in development can't benefit patients today. Waiting two years for a treatment that might produce 3-4% additional weight loss means deferring the substantial health benefits available right now from current medications.

​

What About Current Patients?

​

This is where I try to inject some practical wisdom gained from years of clinical practice. If you're currently on Mounjaro or Wegovy and achieving good results with acceptable side effects, switching to something else when it becomes available isn't automatically better. Stability and consistency matter in weight management. You've invested months in treatment, your body has adapted to the medication, you've established routines and habits. Disrupting this for theoretically marginal improvements carries risks.

I have patients who've lost 25-30kg on current medications. They're maintaining that loss, they feel well, their metabolic markers have transformed. The idea that they should switch to something new purely because it's new doesn't hold up to clinical scrutiny. If you're meeting your goals, keep doing what works.

That said, not everyone responds optimally to current options. I've worked with patients who've tried both semaglutide and tirzepatide without achieving expected results, despite good adherence and comprehensive lifestyle support. For them, emerging alternatives with different mechanisms might offer genuine advantages. This represents a valid reason to maintain awareness of pipeline developments and discuss future options with your prescriber.

​

The Side Effect Reality

​

All these medications, current and emerging, share certain side effect profiles because they work through related mechanisms. Gastrointestinal symptoms—nausea, vomiting, diarrhea, constipation—affect most patients to some degree during dose escalation. The severity varies enormously between individuals in ways we can't reliably predict.

I always counsel patients that the first 6-8 weeks often involve some GI adjustment. For most, symptoms remain manageable and improve over time. For perhaps 5-10%, side effects become treatment-limiting despite our best management strategies. This reality won't fundamentally change with newer medications, though the balance of side effects might shift slightly depending on specific mechanisms.

The class warnings remain relevant for all these agents: potential thyroid concerns based on animal data, pancreatitis risk, gallbladder disease associated with rapid weight loss. These aren't reasons to avoid treatment—the benefits far outweigh risks for most appropriate patients—but they require informed consent and ongoing monitoring.

​

Timing and Access Considerations

​

Let's talk practically about timelines, because this affects decision-making for patients considering treatment today. Retatrutide and CagriSema are currently in Phase 3 trials. Assuming successful completion, optimistic timelines place regulatory submissions in late 2025 or early 2026. MHRA review takes 12-18 months typically. NICE technology appraisal for NHS commissioning adds another 12-18 months.

This means NHS availability of these agents, if everything proceeds perfectly, likely sits somewhere in 2027-2028. Private prescription might come 12-18 months earlier, assuming clinicians are willing to prescribe off-label while NICE guidance is pending. But expect limited initial supplies and premium pricing.

For patients considering weight loss treatment today, waiting 2-3 years means deferring substantial health benefits that current medications deliver right now. The metabolic improvements from losing 15-20% body weight—reduced diabetes risk, improved cardiovascular health, decreased joint strain, enhanced psychological wellbeing—are tangible and immediate. Deferring these benefits while waiting for medications that might offer incrementally better results strikes me as poor clinical reasoning for most patients.

​

The Comprehensive View

​

What excites me most about these developments isn't actually the specific percentage improvements in trial outcomes, though those are impressive. It's the expanding toolkit and the validation that pharmaceutical innovation in obesity treatment remains active and productive. Having multiple options means better ability to individualize treatment—matching patients to medications based on their specific circumstances, preferences, and response patterns.

But I return repeatedly to a point I emphasize with every patient: medication is a tool, not a complete solution. Over twenty years, I've watched patients achieve extraordinary outcomes, and I've observed complete weight regain when treatment was discontinued without addressing underlying lifestyle factors. The most successful patients invariably combine pharmacotherapy with genuine dietary modification, regular physical activity, behavioural support, and long-term commitment to new habits.

One patient comes to mind—Claire, who lost 32kg over twenty months on tirzepatide while working with a dietitian, joining a gym, and attending our support groups. When supply issues forced a two-month treatment gap, she regained only 2kg because the lifestyle foundation was solid. Another patient, Michael, lost 28kg on semaglutide but regained 22kg within six months of discontinuing because the medication had been doing all the work and he'd never developed sustainable habits. The medication created the opportunity; the lifestyle changes determined long-term success.

​

My Clinical Recommendations

​

For patients currently on GLP-1 medications achieving good results: continue your current treatment. Don't disrupt successful therapy chasing theoretical improvements. If you're losing weight steadily, tolerating medication well, and feeling positive about your progress, that's success. Protect it.

For patients considering starting treatment: don't wait for future medications. The health benefits of weight loss begin immediately and compound over time. Starting effective treatment today delivers tangible outcomes that waiting two years to access marginally better options cannot match.

For patients who've tried current options without adequate response: this is where pipeline awareness matters most. Discuss with your prescriber whether persisting with current treatment, optimizing lifestyle factors, or waiting for alternative mechanisms makes most sense for your individual situation.

​

Looking Forward

​

We're living through what historians will likely recognize as a transformative period in obesity medicine. The therapeutic nihilism that characterized this field for decades—the sense that we had nothing effective to offer beyond lifestyle advice and bariatric surgery—has given way to genuine optimism backed by robust clinical evidence.

The medications we have today work remarkably well for most appropriately selected patients. The medications in development may work even better. But the fundamental principles don't change: comprehensive assessment, individualized treatment plans, realistic expectations, ongoing monitoring and support, integration with lifestyle modification, and long-term commitment to sustainable change.

That's the framework within which medication selection occurs, whether we're discussing current options or future possibilities. The specific agent matters less than the comprehensive approach surrounding its use.

​

References

​

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.

2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.

3. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide plus once-weekly semaglutide versus once-weekly semaglutide in adults with obesity (REDEFINE 1): a multicentre, randomised, double-blind, parallel-group, phase 2 trial. Lancet. 2023;402(10408):1305-1316.

4. Urva S, Coskun T, Loghin C, et al. The novel GIP and GLP-1 receptor agonist tirzepatide transiently improves beta-cell function in adults with type 2 diabetes. Cell Metab. 2022;34(11):1568-1580.

5. National Institute for Health and Care Excellence. Tirzepatide for treating type 2 diabetes. Technology appraisal guidance [TA924]. 2023.

6. Frias JP, Hsia S, Erol HK, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10410):472-483.